Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants had given written informed consent to participate in the study in accordance with local regulations.~* Adult participants 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analog delivered. via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).~* Willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary as required per protocol.~* At the Screening Visit, A1C must be between 7.0% to 11.0%.~* Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test .~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to randomization.~* Chronic systemic corticosteroid use.~* Type 2 diabetes mellitus (T2D), or severely uncontrolled T1D as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
- Sotagliflozin 200 milligrams (mg) (Type: EXPERIMENTAL): Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).